The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies.
Stealth Biotherapeutics Inc. has been awarded the Kyle Bryant Translational Research Award from the Friedreich’s Ataxia Research Alliance (FARA) to evaluate mitochondria-targeted molecule SBT-589 in Friedreich’s ataxia (FA).
Integrated Nanotherapeutics Inc. has received an award from Breakthrough T1D (formerly Juvenile Diabetes Research Foundation Ltd. [JDRF]) to advance the company’s technology to induce immune tolerance in type 1 diabetes.
NRG Therapeutics Ltd. has been awarded a grant from Target ALS Foundation to support its discovery program for a treatment for amyotrophic lateral sclerosis (ALS).
Acurastem Inc. has secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to facilitate the development of its UNC13A program toward clinical trials for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Mestag Therapeutics Ltd. has been awarded a £1.5 million ($1.9 million) grant from Innovate UK’s Cancer Therapeutics program to accelerate the development of MST-0300.
Eydisbio Inc. has been awarded a $2.6 million phase II Small Business Innovation Research (SBIR) grant from the National Institute of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) to support its ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis.
Anivive Lifesciences Inc., a One Health technology company, reported the NIH’S National Institute of Allergy and Infectious Diseases (NIAID) has awarded grant funding worth up to $33 million to the company to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.
RSS
